Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota

A. T. Sougiannis, B. N. VanderVeen, R. T. Enos, K. T. Velazquez, J. E. Bader, M. Carson, I. Chatzistamou, M. Walla, M. M. Pena, J. L. Kubinak, M. Nagarkatti, James Carson, E. A. Murphy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Emerging evidence suggests that gut microbiota may influence the response to chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response. 50 C57BL/6 were randomized into four groups; Control + Vehicle (n = 10), Control + 5FU (n = 10), AOM/DSS + Vehicle (n = 15), and AOM/DSS + 5FU (n = 15). CRC was induced chemically by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 5FU (cycle 1: 40 mg/kg, cycle 2 + 3: 20 mg/kg). Functional tests (grip strength and run-to-fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the second cycle of 5FU. Following the third 5FU cycle, mice were euthanized and the colon was evaluated for expression of inflammatory genes using RT-qPCR and stool samples were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota transplantation from 5FU treated mice to control mice (n = 10–15/group) to determine whether 5FU associated changes in the microbiota could influence functional measures and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending decrease in run-to-fatigue performance in cancer mice (p = 0.06). Select intestinal inflammatory genes were significantly elevated with 5FU treatment and this was further exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and altered select colon inflammatory markers (p < 0.05). This study provides evidence of an effect of 5FU on inflammatory responses and functional measures in a mouse model of CRC and suggests that gut microbes may play a role in some, but not all, 5FU related perturbations.

Original languageEnglish (US)
Pages (from-to)44-55
Number of pages12
JournalBrain, Behavior, and Immunity
Volume80
DOIs
StatePublished - Aug 1 2019

Fingerprint

Fluorouracil
Inflammation
Drug Therapy
Azoxymethane
Dextran Sulfate
Colon
Colorectal Neoplasms
Microbiota
Gastrointestinal Microbiome
Hand Strength
Fatigue
Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Cite this

Sougiannis, A. T., VanderVeen, B. N., Enos, R. T., Velazquez, K. T., Bader, J. E., Carson, M., ... Murphy, E. A. (2019). Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. Brain, Behavior, and Immunity, 80, 44-55. https://doi.org/10.1016/j.bbi.2019.02.020

Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. / Sougiannis, A. T.; VanderVeen, B. N.; Enos, R. T.; Velazquez, K. T.; Bader, J. E.; Carson, M.; Chatzistamou, I.; Walla, M.; Pena, M. M.; Kubinak, J. L.; Nagarkatti, M.; Carson, James; Murphy, E. A.

In: Brain, Behavior, and Immunity, Vol. 80, 01.08.2019, p. 44-55.

Research output: Contribution to journalArticle

Sougiannis, AT, VanderVeen, BN, Enos, RT, Velazquez, KT, Bader, JE, Carson, M, Chatzistamou, I, Walla, M, Pena, MM, Kubinak, JL, Nagarkatti, M, Carson, J & Murphy, EA 2019, 'Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota', Brain, Behavior, and Immunity, vol. 80, pp. 44-55. https://doi.org/10.1016/j.bbi.2019.02.020
Sougiannis, A. T. ; VanderVeen, B. N. ; Enos, R. T. ; Velazquez, K. T. ; Bader, J. E. ; Carson, M. ; Chatzistamou, I. ; Walla, M. ; Pena, M. M. ; Kubinak, J. L. ; Nagarkatti, M. ; Carson, James ; Murphy, E. A. / Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. In: Brain, Behavior, and Immunity. 2019 ; Vol. 80. pp. 44-55.
@article{cbe330d787904c94b5a8005e9da2ffdc,
title = "Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota",
abstract = "Emerging evidence suggests that gut microbiota may influence the response to chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response. 50 C57BL/6 were randomized into four groups; Control + Vehicle (n = 10), Control + 5FU (n = 10), AOM/DSS + Vehicle (n = 15), and AOM/DSS + 5FU (n = 15). CRC was induced chemically by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2{\%} and 1{\%}) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 5FU (cycle 1: 40 mg/kg, cycle 2 + 3: 20 mg/kg). Functional tests (grip strength and run-to-fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the second cycle of 5FU. Following the third 5FU cycle, mice were euthanized and the colon was evaluated for expression of inflammatory genes using RT-qPCR and stool samples were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota transplantation from 5FU treated mice to control mice (n = 10–15/group) to determine whether 5FU associated changes in the microbiota could influence functional measures and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending decrease in run-to-fatigue performance in cancer mice (p = 0.06). Select intestinal inflammatory genes were significantly elevated with 5FU treatment and this was further exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and altered select colon inflammatory markers (p < 0.05). This study provides evidence of an effect of 5FU on inflammatory responses and functional measures in a mouse model of CRC and suggests that gut microbes may play a role in some, but not all, 5FU related perturbations.",
author = "Sougiannis, {A. T.} and VanderVeen, {B. N.} and Enos, {R. T.} and Velazquez, {K. T.} and Bader, {J. E.} and M. Carson and I. Chatzistamou and M. Walla and Pena, {M. M.} and Kubinak, {J. L.} and M. Nagarkatti and James Carson and Murphy, {E. A.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.bbi.2019.02.020",
language = "English (US)",
volume = "80",
pages = "44--55",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota

AU - Sougiannis, A. T.

AU - VanderVeen, B. N.

AU - Enos, R. T.

AU - Velazquez, K. T.

AU - Bader, J. E.

AU - Carson, M.

AU - Chatzistamou, I.

AU - Walla, M.

AU - Pena, M. M.

AU - Kubinak, J. L.

AU - Nagarkatti, M.

AU - Carson, James

AU - Murphy, E. A.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Emerging evidence suggests that gut microbiota may influence the response to chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response. 50 C57BL/6 were randomized into four groups; Control + Vehicle (n = 10), Control + 5FU (n = 10), AOM/DSS + Vehicle (n = 15), and AOM/DSS + 5FU (n = 15). CRC was induced chemically by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 5FU (cycle 1: 40 mg/kg, cycle 2 + 3: 20 mg/kg). Functional tests (grip strength and run-to-fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the second cycle of 5FU. Following the third 5FU cycle, mice were euthanized and the colon was evaluated for expression of inflammatory genes using RT-qPCR and stool samples were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota transplantation from 5FU treated mice to control mice (n = 10–15/group) to determine whether 5FU associated changes in the microbiota could influence functional measures and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending decrease in run-to-fatigue performance in cancer mice (p = 0.06). Select intestinal inflammatory genes were significantly elevated with 5FU treatment and this was further exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and altered select colon inflammatory markers (p < 0.05). This study provides evidence of an effect of 5FU on inflammatory responses and functional measures in a mouse model of CRC and suggests that gut microbes may play a role in some, but not all, 5FU related perturbations.

AB - Emerging evidence suggests that gut microbiota may influence the response to chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response. 50 C57BL/6 were randomized into four groups; Control + Vehicle (n = 10), Control + 5FU (n = 10), AOM/DSS + Vehicle (n = 15), and AOM/DSS + 5FU (n = 15). CRC was induced chemically by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 5FU (cycle 1: 40 mg/kg, cycle 2 + 3: 20 mg/kg). Functional tests (grip strength and run-to-fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the second cycle of 5FU. Following the third 5FU cycle, mice were euthanized and the colon was evaluated for expression of inflammatory genes using RT-qPCR and stool samples were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota transplantation from 5FU treated mice to control mice (n = 10–15/group) to determine whether 5FU associated changes in the microbiota could influence functional measures and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending decrease in run-to-fatigue performance in cancer mice (p = 0.06). Select intestinal inflammatory genes were significantly elevated with 5FU treatment and this was further exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and altered select colon inflammatory markers (p < 0.05). This study provides evidence of an effect of 5FU on inflammatory responses and functional measures in a mouse model of CRC and suggests that gut microbes may play a role in some, but not all, 5FU related perturbations.

UR - http://www.scopus.com/inward/record.url?scp=85062455494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062455494&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2019.02.020

DO - 10.1016/j.bbi.2019.02.020

M3 - Article

AN - SCOPUS:85062455494

VL - 80

SP - 44

EP - 55

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

ER -